This publication by the Küster group presents a robust workflow to support the analysis of large cohorts of patient samples using formalin-fixed paraffin-embedded FFPE tissue. They make use of online fractionation by FAIMS requiring 50% less sample than conventional high pH fractionation.

This publication by the Trudel group describes the development of a non-invasive MS-based assay, called EasyM, which is used to assess minimal residual disease, a measure of depth of remission to treatment, which has become an important parameter in assessing the disease burden in multiple myeloma.

This publication is a major collaboration led by the Knight group at University of Oxford describing the hallmarks of Covid-19 severity and specificity. It is an integrative multi-omics analysis, where the Evosep One was used for measuring 340 plasma proteomes providing excellent patient stratification.

Proteomics is a field in continuous development, where robust and optimized processes throughout the entire workflow – from sample preparation to acquisition strategies and downstream data processing are the goal. In recent years, data independent workflows have gained increased interest due to its high degree of reproducibility, better sensitivity and accuracy for quantification compared to classic data-dependent workflows.

Proteomics is a field in continuous development, where robust and optimized processes throughout the entire workflow – from sample preparation to acquisition strategies and downstream data processing are the goal. In recent years, data independent workflows have gained increased interest due to its high degree of reproducibility, better sensitivity and accuracy for quantification compared to classic data-dependent workflows.

Proteomics is a field in continuous development, where robust and optimized processes throughout the entire workflow – from sample preparation to acquisition strategies and downstream data processing are the goal. In recent years, data independent workflows have gained increased interest due to its high degree of reproducibility, better sensitivity and accuracy for quantification compared to classic data-dependent workflows.

Dynamic change in subcellular localization of signaling proteins is a general concept that eukaryotic cells evolved for eliciting a coordinated response to stimuli. Mass spectrometry (MS)-based proteomics in combination with subcellular fractionation can provide comprehensive maps of spatio-temporal regulation of cells, but involves laborious workflows that does not cover the phospho-proteome level.

Single-cell technologies are revolutionizing biology but have so far mainly been limited to imaging and deep sequencing. However, proteins are the main drivers of cellular function and in-depth characterization of individual cells by mass spectrometry (MS)- based proteomics would thus be highly valuable and complementary.

Proteomics workflows have become increasingly successful in the characterization of complex proteomes in great depth. Application to large sample cohorts requires a high degree of reproducibility and data completeness, which makes DIA workflows interesting.

In collaboration with Odense University Hospital in Denmark, the Mann group at Novo Nordisk Foundation Center for Protein Research have developed a machine learning model based on their biomarker panel, which for the first time outperforms existing tests, laying the foundation for a generic proteomics liver health assessment.

We are getting a lot of questions about Evosep these days. To fill you in, we would like to share our thoughts on frequently asked questions about Evosep – and hopefully provide some inspiration to how our technology will support your research.

Neurodegenerative diseases are characterized by an accumulation of misfolded proteins. Cells normally recognize misfolded proteins and attempt to refold or to pass them on for proteasomal degradation. Chaperone proteins are central to recognizing and in refolding client proteins. When chaperone proteins fail to fulfill this function, conformationally altered proteins accumulate and can cause cell death.

In a collaboration with Thermo Fisher Scientific, the Olsen Group and Novo Nordisk Foundation Center for Protein Research have described the new Thermo Scientific™ Orbitrap Exploris™ 480 mass spectrometer for high-throughput analyses with short gradients using the Evosep One.

Three years ago, the Evosep One technology was developed to target the growing need for high-throughput solutions for clinical and large-scale proteomics. Striking the right balance in performance, delivering both sensitivity, speed and robustness is an essential part of the Evosep One technology.

A part of the Evosep way is sharing every step of our journey with you and this year we took a look on what made 2019, highlighting some of our most popular posts from LinkedIn.

Facilitating early adequate therapy for patients infected by multidrug resistant bacteria calls for a novel precise and rapid diagnostic method as today’s resistance determinations are often slow and expensive.

This month we have been promoting a survey asking lab users within the field to share their thoughts on what matters in clinical proteomics. We see innovation as a community effort, and we look forward to share the results back with you.

Together, Thermo Fisher Scientific and Evosep are on a joint mission to develop standardized and scalable plasma protein quantitative profiling workflows. Our recent developments have been featured in an application note by the Precision Medicine Science Centre led by Dr. Emily Chen.

The need for scalable methods for functional annotation of phosphotyrosine sites has led the Olsen group, Novo Nordisk Foundation Center for Protein Research in Copenhagen, to develop a new mass spectrometry-based workflow for high-throughput analyses. In a recent study, they implemented this new workflow used to describe how cancer mutations close to tyrosine phosphorylation sites in the EGF receptor rewire signaling pathways by switching protein interactors.

Since launching the Evosep One system at HUPO 2017, we have made many installations and see increasing demand in North America.

HUPO (The Human Proteome Organization) is an annual conference presenting and promoting proteomics through international collaborations, fostering the development of new technologies, techniques and training.

Jonathan Krieger, PhD, Senior Applications Scientist at Bioinformatics Solutions presented “Evosep One Enables Robust Deep Proteome Coverage Using Tandem Mass Tags while Significantly Reducing Instrument Time” showcasing recent data from the SPARC Biocentre at the Hospital for Sick Children.

Senior Scientific Advisor Thomas Angel at GSK presents Targeted assay development for quantifying protein half-life over a range of mouse tissues. Take me to the webinar

WASHINGTON, March 4, 2019 /PRNewswire/ — At the 15th Annual Conference of the US Human Proteome Organization (www.ushupo.org), Bruker and Evosep announce further progress in high-sensitivity, high-throughput plasma-proteomics using the timsTOF Pro mass spectrometer connected to an Evosep One low-flow chromatography system.

Orlando, Florida – HUPO 2018 – (October 1, 2018) Today, at the 17th Human Proteome Organization World Congress, Biognosys and Evosep promote a robust, high-throughput workflow for clinical research proteomics.

With ASMS this year, the summer was off to a great start. We are delighted to see the continuing use of our technology in various applications. Together with our collaboration partners we presented a number of posters, press releases and seminars which are now available for view/ download at our new ASMS landing site.

(June 4, 2018) Today, at the 66th Conference on Mass Spectrometry and Allied Topics, Thermo Scientific and Evosep announced a joint effort to develop and promote robust, high-throughput workflows for clinical proteomics.

Alphalyse sees an increasing demand for robust and high throughput LC/MS especially for HCP analysis. Recently they invested in liquid handling robotics and last week we installed Evosep One. Senior Scientist Jakob Bunkenborg elaborates on the decision.

A collaboration between Mathias Mann’s lab and the Jesper Olsen Group together with Head of Applications at Evosep, Nicholai Bache, has just submitted key results to MCP. Their research shows how to further integrate MS-based proteomics into biomedical research and clinical settings while ensuring high throughput and robustness using the Evosep One.

We are getting a lot of questions about Evosep these days, and we are excited that you want to know who we are and what we do. To answer the most asked question and to share our perspectives on clinical proteomics we have conducted four short blog post for you to read.

It has been a pleasure introducing you to who we are. We hope you know us a little better by now, and will enjoy reading about our future thoughts on mass spectrometry-based omics.

Last time we talked about our view on proteomics right now, and today we are introducing you to the Evosep One – a novel separation solution designed for fast and robust separation of omics samples in large clinical cohort studies (primarily proteomics and metabolomics).

Welcome back. It is a great pleasure for us to introduce you to our view on clinical proteomics right now.

ASMS is the largest annual gathering of mass spectrometry scientists in the world and we are excited to be there, showcasing the next generation of technology for MS based omics.

Bruker’s new press release announce the integration of the Evosep One with Brukers timsTOF Pro mass spectrometer for high sensitivity proteomics.

Dr. Holms explains how clinical proteomics can impact patient care

Please join us in welcoming Erik Verschuuren to Evosep Biosystems as our new Head of Global Sales and hear his thoughts on clinical proteomics and why he joined Evosep.

Nicolai and Ole unbox and assemble a Evosep One instrument from scratch

Professor Akhilesh Pandey, M.D., Ph.D. talks about the current situation for clinical proteomics and what is looming on the horizon.

Dr. Conrads explains how clinical proteomics can improve cancer treatment with early detection, molecular diagnosis and increased precision.

Professor Phil Robinson from ProCan in Sydney

Professor Matthias Mann from MPI in Martinsried

Perspectives of clinical proteomics for precision medicine and the resulting demands on front-end separation for mass spectrometric analysis

Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics. We will make sample preparation and separation for mass spectrometry analysis 100 times more robust and 10 times faster to enable truly large cohort studies and provide the foundation for precision medicine.

Biomarker tests have become an important tool in clinical diagnostics. The PSA test evaluates the risk for prostate cancer, and inflammatory and myocardial panels save lives when performed fast enough. Still biomarkers, especially protein biomarkers, are not yet used to their full potential. While novel approaches employ mass spectrometry instead of immunoassay detection, one bottleneck remains: the need for robust, fast, and efficient sample preparation.

Almost 50 years after their inception, immunoassays (IAs) are still the predominant method in biomarker diagnostics. IAs are used to detect pregnancies, infections, allergies, and many other health events in our lives. But for how much longer?

Biomarker tests have become an important tool in clinical diagnostics. The PSA test evaluates the risk for cancer, and inflammatory and myocardiac panels save lives when performed fast enough. Still biomarkers, especially protein biomarkers, are not used to their full potential. While novel approaches employ mass spectrometry instead of immunoassay detection, one bottleneck remains: the need for robust, fast, and efficient sample preparation.

Vlog13: Nicolai walks through the new industrial design cabinet

Vlog12: Nicolai Bache shows the pump module in the newly designed cassette format.

Vlog11: Update from our prototype running in Martinsried @ Professor Mann.

Vlog10: How we test the lifetime of our individual hardware componants

Many areas in clinical proteomics could benefit from a broader adoption of liquid chromatography mass spectrometry (LC/MS) methods. What needs to be done to make LC/MS a standard technique in the clinic?

Vlog09: We have now installed our second beta instrument at the University at Southern Denmark.

Vlog08: Installation of our first prototype at the Max Planck Institute (MPI) in Martinsried.

Vlog07: Nicolai Bache and Ole Hørning gives a status update on LP1 including data and recent development progress.

Vlog06: Jesper Matthiesen describes how he is prototyping our syringe pump PCB

Vlog05: Nicolai Bache takes a tour around our first lap prototype

Vlog04: Pumps

Vlog03: Nicolai Bache explains the technical details of our very first mockup

Vlog02: Technology and innovation introduction. Nicolai explains the concepts we are implementing to facilitate clinical proteomics.

Welcome to our video blog. Here you can follow our journey from sketches on board to the final product.

Cohort studies are essential in the discovery and validation of protein biomarkers. Every day, clinical proteomics labs evaluate patient samples to correlate protein patterns with a specific status – e.g., healthy vs. pathogenic, or therapeutically responsive vs. non-responsive.